On June 17, 2025, Materna Medical, Inc., a leading innovator in women’s pelvic health solutions, announced the completion of a recent close within an ongoing $20 million Series B2 financing round. The round welcomed new funds GLIN Impact Capital, Wealthing VC Club, and Citrine Angels, and was led by InnovaHealth Partners and other key existing investors Wavemaker Three-Sixty Health, Kimera Limited, Women’s Venture Capital Fund, and Golden Seeds. Wilson Sonsini Goodrich & Rosati advised Materna Medical on the transaction.

Materna Medical is a novel OBGYN platform company defining a $25 billion market with core technologies addressing unmet needs in women’s pelvic health. Headquartered in Mountain View, California, Materna pulls from the top minds in MedTech to transform the standard of care in OBGYN. With a diverse team of engineers, scientists, researchers, and commercial leaders, Materna Medical’s mission is to empower women to protect their pelvic health.

The Wilson Sonsini team that advised Materna Medical on the transaction includes Brian Appel, Davelyn Couch, Roy Argand, and Tim Ingram.

For more information, please see Materna Medical’s press release.